🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

19 recruiting trials

for Advanced Clear Cell Renal Carcinoma (Ccrcc)

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410Phase 138 sites📍 Phoenix📍 Tucson📍 Los Angeles Kura Oncology, Inc. · Tests: Darlifarnib, Cabozantinib, Adagrasib GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites📍 New York📍 New York📍 Huntersville GI Innovation, Inc. · Tests: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT07011719Phase 3183 sites📍 Gilbert📍 Goodyear📍 Phoenix Arcus Biosciences, Inc. · Tests: Casdatifan, Cabozantinib, Placebo Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) NCT05665361Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Sasanlimab, Palbocicilib A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NCT06805825Phase 15 sites📍 Ann Arbor📍 Cleveland📍 Portland Novelty Nobility, Inc. · Tests: NN3201 Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma NCT07300241Phase 114 sites📍 Duarte📍 San Diego📍 New Haven Neomorph, Inc · Tests: NEO-811 A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body NCT06413680Phase 1, Phase 211 sites📍 Los Angeles📍 San Francisco📍 North Haven Regeneron Pharmaceuticals · Tests: REGN10597, Cemiplimab A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites📍 Duarte📍 La Jolla📍 Ann Arbor Incyte Corporation · Tests: INCA036873 A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors NCT05706129Phase 1, Phase 210 sites📍 Melbourne📍 Sydney📍 Clermont-Ferrand Lumara Bio Oncologics GmbH · Tests: [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors NCT05176483Phase 1122 sites📍 Phoenix📍 Tucson📍 Palo Alto Exelixis · Tests: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) NCT07195682Phase 111 sites📍 Boston📍 New York📍 Philadelphia Bristol-Myers Squibb · Tests: BMS-986506, Pumitamig, Ipilimumab A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma NCT07123090Phase 22 sites📍 Boston📍 Boston Stephanie Berg · Tests: Sasanlimab, Palbociclib, Axitinib A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors NCT06270706Phase 122 sites📍 New Haven📍 Atlanta📍 Grand Rapids Pliant Therapeutics, Inc. · Tests: PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095 Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC NCT07197580Phase 35 sites📍 Sydney📍 Wollongong📍 Heidelberg Telix Pharmaceuticals (Innovations) Pty Limited · Tests: 177Lu-TLX250 Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma NCT05287945Phase 1, Phase 210 sites📍 Orange📍 Palo Alto📍 San Francisco Oncorena AB · Tests: Orellanine A Beta-only IL-2 ImmunoTherapY Study NCT05086692Phase 1, Phase 228 sites📍 San Diego📍 San Francisco📍 Santa Monica Medicenna Therapeutics, Inc. · Tests: MDNA11, Pembrolizumab (KEYTRUDA®) A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) NCT07188896Phase 25 sites📍 Washington D.C.📍 Chapel Hill📍 Hershey Brian Rini · Tests: Fianlimab, Ipilimumab, Nivolumab, Cemiplimab Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors NCT06750185Phase 1, Phase 211 sites📍 Louisville📍 Grand Rapids📍 Huntersville BioNTech SE · Tests: BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy